ANIK

Business Context and Reporting Period

Company: Anika Therapeutics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2008
Business Overview: Anika develops, manufactures, and commercializes therapeutic products based on hyaluronic acid (HA) for tissue protection, healing, and repair. Key products include ORTHOVISC (osteoarthritis), AMVISC (ophthalmic), HYVISC (veterinary), and the recently launched MONOVISC. The company operates in the U.S. and internationally through distribution partners such as DePuy Mitek (J&J) and Bausch & Lomb.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 27.6% for the quarter and 33.0% for the six-month period compared to 2007. Product revenue grew 32.3% (Q2) and 38.8% (YTD).
• Segment Performance:
  • Joint Health: Revenue surged 79.5% (Q2) and 67.7% (YTD), driven by strong domestic sales of ORTHOVISC via DePuy Mitek and international expansion.
  • Veterinary: Revenue increased 45.5% (Q2) and 52.3% (YTD) due to partner sales efforts for HYVISC.
  • Ophthalmic: Revenue decreased 11.3% in Q2 but increased 7.8% YTD, attributed to order timing and inventory building by partners.
• Profitability: Net income decreased 40.4% for the quarter and 44.2% for the six-month period compared to 2007, despite revenue growth. This was primarily due to significant increases in operating expenses.
• Expense Increases:
  • R&D: Increased 65.1% (Q2) and 71.0% (YTD) due to clinical trials for MONOVISC and CINGAL, and manufacturing scale-up.
  • SG&A: Increased 67.8% (Q2) and 80.8% (YTD) driven by new product launch marketing, personnel costs, and expenses related to the new Bedford facility.
• Capital Expenditures: Investing cash outflows increased significantly to $8.1 million (YTD) from $6.3 million in 2007, primarily for the construction of a new $30 million facility.
• Debt: The company entered a $16 million credit facility in January 2008 and had $8 million outstanding as of June 30, 2008. No long-term debt was outstanding in the prior year.

Guidance, Outlook, and Risks

• Outlook: Management expects ORTHOVISC revenue to increase in 2008 both domestically and internationally. Ophthalmic revenue is expected to see only a slight increase. HYVISC sales are expected to increase overall despite a potential dip in Q3.
• Product Launches: MONOVISC was launched in Europe in Q2 2008. ELEVESS (aesthetic dermatology) is expected to commence shipments in the U.S. in Q3 2008. Clinical trials for CINGAL are expected to commence in 2009.
• Facility Project: The new Bedford facility (HQ, R&D, manufacturing) is expected to cost approximately $30 million. Validation is expected late 2008 into 2009. The company expects to occupy the existing facility through end of 2009.
• Risks & Contingencies:
  • FDA Warning Letter: The company received a Warning Letter regarding its Woburn facility. A corrective action plan is in place, but failure to comply could materially adversely affect operations.
  • Trademark Opposition: Colbar Lifescience Ltd. (J&J subsidiary) filed an opposition to the ELEVESS trademark. The proceeding is suspended while settlement is explored; no loss accrual was recorded.
  • Regulatory Approval: Success depends on FDA and EU approvals for new products and the re-qualification of the new facility.

Investor Verification Checklist

• Verify the status of the FDA Warning Letter response and the timeline for the new Bedford facility validation.
• Monitor the outcome of the ELEVESS trademark opposition with Colbar Lifescience Ltd.
• Track the commercial launch progress of ELEVESS in Q3 2008 and MONOVISC in international markets.
• Assess the sustainability of the increased operating expenses (R&D and SG&A) relative to future revenue growth.
• Review the company's ability to meet debt covenants (quick ratio and fixed charge coverage) as capital expenditures continue.